ClinicaliQ Trial Snapshot
- An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis — Active Not Recruiting • Phase II • Rheumatology • NCT05848258.
- A new drug (LY3871801) is being tested for safety and effectiveness in adults with moderate-to-severe rheumatoid arthritis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA). Conditions: Rheumatoid Arthritis Interventions: LY3871801, Placebo Lead Sponsor: Eli Lilly and Company Planned Enrollment: 164 participants